Filing identity and business context
Important mismatch: The supplied filing is MEI Pharma, Inc.’s Form 10-K for the fiscal year ended June 30, 2022—not a filing for Lite Strategy, Inc. or 2020 Q4. This summary reflects the supplied filing; it does not provide a separate 2020 Q4 result.
MEI Pharma is a clinical-stage oncology company developing zandelisib, voruciclib and ME-344. It had no commercialized drug candidates. Most reported revenue came from its zandelisib collaboration with Kyowa Kirin Company (KKC).
Financial results and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $40.7 million | $34.8 million |
| Research and development | $85.6 million | $69.4 million |
| General and administrative | $30.5 million | $24.4 million |
| Operating loss | $75.5 million | $60.4 million |
| Net loss | $54.5 million | $41.3 million |
| Net cash used in operating activities | $48.7 million | $32.0 million |
- Revenue increased $5.9 million, primarily from greater reimbursement of KKC-related research and development costs. FY2022 revenue included $37.3 million for development services and $3.4 million for pass-through services; there was no product-sales revenue.
- Net loss included a non-cash gain of $20.8 million from remeasuring warrant liabilities. Excluding that gain, the filing reports a FY2022 loss of approximately $75.2 million, versus $59.4 million in FY2021. The comparable non-cash warrant gain in FY2021 was $18.1 million.
- At June 30, 2022, cash, cash equivalents and short-term investments totaled $153.3 million, versus $153.4 million a year earlier. Management believed available resources would fund operations for at least 12 months from the filing’s issuance.
- Current assets were $167.1 million and current liabilities $24.4 million. The balance sheet reports no borrowings or other debt; liabilities included $95.4 million of deferred revenue, lease liabilities and a $1.6 million warrant liability.
- Financing cash flow was $49.1 million, including $48.7 million net proceeds from an underwritten stock offering of 20.125 million shares. Share count rose to 133.2 million from 112.6 million. Operating cash use was $48.7 million after receipt of $20 million in KKC milestones.
- The filing gives no conventional revenue or earnings guidance. Management expected R&D spending to increase and anticipated continued operating losses and negative operating cash flow.
Material changes and developments
- The FDA advised that randomized evidence is needed to assess PI3K inhibitor safety and efficacy, discouraged a filing based on the single-arm TIDAL Phase 2 study, and recommended continued dose exploration. MEI consequently no longer planned to seek FDA approval based on TIDAL alone.
- MEI continued the randomized Phase 3 COASTAL trial of zandelisib plus rituximab versus standard chemoimmunotherapy, intended to support U.S. and global marketing applications. The trial planned to enroll 534 patients.
- In TIDAL’s follicular lymphoma primary efficacy population, reported overall response rate was 70.3% and complete response rate was 35.2%. These interim results were not considered sufficient by the FDA to support the planned single-arm filing.
- FY2022 R&D rose $16.2 million, largely reflecting zandelisib development and higher activity across programs; G&A rose $6.1 million. The net loss increased, and operating cash use also increased.
- MEI identified material errors in its KKC revenue-recognition accounting and restated FY2020 and FY2021 financial statements and interim periods through December 2021. Management concluded internal control over financial reporting and disclosure controls were ineffective as of June 30, 2022; remediation was underway. The auditor gave an unqualified opinion on the financial statements but was not engaged to audit internal controls.
Outlook, risks and contingencies
- KKC and MEI share U.S. zandelisib development costs and profits 50/50; KKC has ex-U.S. rights and is generally responsible for ex-U.S. costs. MEI received two $10 million COASTAL-related milestones in FY2022. Potential future KKC milestones and ex-U.S. royalties remain contingent.
- COASTAL sites planned for Ukraine and Russia were suspended following the military conflict; replacement sites or enrollment elsewhere may affect recruitment timing. COVID-19 also had affected trial enrollment and could continue to disrupt trials, supply and timelines.
- MEI received a Nasdaq notice for failing the $1.00 minimum bid-price requirement. The initial compliance deadline was November 7, 2022; delisting remained a risk if compliance was not regained.
- The company had accumulated losses of $374.2 million and stated that substantial additional funding would eventually be needed. Further equity financing could dilute shareholders; the filing reported $60 million remaining under its ATM facility and $123.4 million available under its shelf registration at year-end.
- Other material risks include clinical-trial failure or adverse effects, regulatory delay, dependence on collaborators and contract manufacturers, competition, and the possibility that patent protection or financing may be inadequate. The filing disclosed no legal proceedings.
Most important facts for investors to verify
- Confirm the intended issuer and period: this document is MEI Pharma’s FY2022 10-K, not Lite Strategy’s 2020 Q4 filing.
- Review the revenue restatement, KKC agreement accounting, and progress of the disclosed control-remediation plan.
- Check current COASTAL enrollment, trial timelines, dose exploration and any subsequent FDA guidance; do not treat TIDAL response data as proof of approval likelihood.
- Verify current cash runway, operating cash burn, financing needs and dilution from equity facilities, options and warrants.
- Check Nasdaq listing status and whether geopolitical or pandemic-related disruptions affected trial recruitment or supply.